Furthermore, inhibiting EZH2 in vivo could not only reduce the frequency of leukemia-initiating cells (LICs) but also improve the survival of mice with MLL-AML (Fujita et al., 2018; Ueda et al., 2014). Here, KMT2A is linked to leukemia.